SPECIFIC BRADYCARDIC AGENTS .1. CHEMISTRY, PHARMACOLOGY, AND STRUCTURE-ACTIVITY-RELATIONSHIPS OF SUBSTITUTED BENZAZEPINONES, A NEW CLASS OF COMPOUNDS EXERTING ANTIISCHEMIC PROPERTIES

被引:72
作者
REIFFEN, M
EBERLEIN, W
MULLER, P
PSIORZ, M
NOLL, K
HEIDER, J
LILLIE, C
KOBINGER, W
LUGER, P
机构
[1] ERNST BOEHRINGER INST ARZNEIMITTELFORSCH,DEPT PHARMACOL,A-1121 VIENNA,AUSTRIA
[2] FREE UNIV BERLIN,INST KRISTALLOG,W-1000 BERLIN 33,GERMANY
关键词
D O I
10.1021/jm00167a033
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Structural modification of the calcium-antagonist verapamil (1) by replacement of the lipophilic α-isopropylacetonitrile moiety by various heterocyclic ring systems has led to a new class of cardiovascular compounds which are characterized by a specific bradycardic activity. These agents reduce heart rate without binding to classical calcium channels or β-adrenoceptors, interacting instead specifically with structures at the sino atrial node. Therefore they have also been termed sinus node inhibitors. The prototype falipamil (2) has been submitted to further optimization mainly by manipulation of the phthalimidine moiety. This has resulted in a second generation of specific bradycardic agents with increased potency and selectively and prolonged duration of action represented by the benzazepinone-derivative UL-FS 49 (4). Structure-activity relationships within this novel class of compounds have revealed a marked dependence of activity on the substitution pattern of the aromatic rings, the nature of the central nitrogen atom, and the length of the connecting alkyl chains. The crucial role of the benzazepinone ring for bradycardic activity can be best explained by its special impact on the overall molecular conformation. © 1990, American Chemical Society. All rights reserved.
引用
收藏
页码:1496 / 1504
页数:9
相关论文
共 84 条
[51]  
OKUNO Y, 1972, CHEM PHARM BULL, V20, P1164
[52]  
PSIORZ M, 1986, 9TH INT S MED CHEM B
[53]   EFFECTS OF THE BRADYCARDIC AGENT UL-FS 49 ON EXERCISE-INDUCED REGIONAL CONTRACTILE DYSFUNCTION IN DOGS [J].
RABERGER, G ;
KRUMPL, G ;
SCHNEIDER, W .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 1987, 14 (03) :343-354
[54]  
REIFFEN M, 1985, Patent No. 161599
[55]  
REIFFEN M, 1985, 189TH ACS NAT M MIAM
[56]  
REIFFEN M, 1982, Patent No. 65229
[57]  
REIFFEN M, 1963, Patent No. 109636
[58]   SPECIFIC BRADYCARDIC AGENTS, A NEW THERAPEUTIC MODALITY FOR ANESTHESIOLOGY - HEMODYNAMIC-EFFECTS OF UL-FS 49 AND PROPRANOLOL IN CONSCIOUS AND ISOFLURANE-ANESTHETIZED DOGS [J].
RILEY, DC ;
GROSS, GJ ;
KAMPINE, JP ;
WARLTIER, DC .
ANESTHESIOLOGY, 1987, 67 (05) :707-716
[59]  
ROTH WR, UNPUB
[60]   COMPARISON OF CARDIOVASCULAR-RESPONSES TO THE BRADYCARDIC DRUGS, ALINIDINE, AQ-A-39, AND MIXIDINE, IN THE ANESTHETIZED DOG [J].
SIEGL, PKS ;
WENGER, HC ;
SWEET, CS .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1984, 6 (04) :565-574